# IMvigor011 (NCT04660344)

> A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04660344
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Muscle-invasive Bladder Cancer
- Interventions: Atezolizumab; Placebo; Signatera
- Enrollment: 761
- Primary outcome: INV-assessed Disease-free Survival (DFS)

## Commentary we found

- X threads: 189
- YouTube: 57
- Podcasts: 51
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imvigor011-nct04660344

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04660344", "email": "<work email>"}; the inbox owner confirms by the emailed link.